- Filed
- Aug 12, 2025 12:00 AM ET
- Period of report
- —
Amendment.
Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Outstanding | Q1 2025 · May 5, 2025 | 15.3M sh |
| Shares Diluted | Q1 2025 · Mar 31, 2025 | 15.26M sh |
| Shares Diluted | Q1 2025 · Mar 31, 2024 | 15.01M sh |
| Stock Repurchased restated | Q1 2025 · Mar 31, 2025 | $8.44K |
| Stock Repurchased | Q1 2025 · Mar 31, 2024 | $6.56K |
| Capex | Q1 2025 · Mar 31, 2025 | $331.51K |
| Capex | Q1 2025 · Mar 31, 2024 | $395.05K |
| Operating Cash Flow | Q1 2025 · Mar 31, 2025 | −$3.7M |
| Operating Cash Flow | Q1 2025 · Mar 31, 2024 | $2.81M |
| Cash And Equivalents | Q1 2025 · Mar 31, 2025 | $21.92M |
| Cash And Equivalents | Q1 2025 · Dec 31, 2024 | $25.05M |
| Cash And Equivalents | Q1 2025 · Mar 31, 2024 | $18.74M |
| Stockholders Equity restated | Q1 2025 · Mar 31, 2025 | $22.81M |
| Stockholders Equity restated | Q1 2025 · Dec 31, 2024 | $20.65M |
| Current Liabilities | Q1 2025 · Mar 31, 2025 | $42.71M |
| Current Liabilities restated | Q1 2025 · Dec 31, 2024 | $49.04M |
| Total Liabilities | Q1 2025 · Mar 31, 2025 | $57.26M |
| Total Liabilities | Q1 2025 · Dec 31, 2024 | $62.48M |
| Current Assets restated | Q1 2025 · Mar 31, 2025 | $70.73M |
| Current Assets restated | Q1 2025 · Dec 31, 2024 | $74.58M |
| Total Assets restated | Q1 2025 · Mar 31, 2025 | $80.09M |
| Total Assets restated | Q1 2025 · Dec 31, 2024 | $83.15M |
| Eps Diluted restated | Q1 2025 · Mar 31, 2025 | $0.06 |
| Eps Diluted | Q1 2025 · Mar 31, 2024 | $0.06 |
| Eps Basic restated | Q1 2025 · Mar 31, 2025 | $0.06 |
| Eps Basic | Q1 2025 · Mar 31, 2024 | $0.06 |
| Sga Expense | Q1 2025 · Mar 31, 2025 | $10.78M |
| Sga Expense restated | Q1 2025 · Mar 31, 2024 | $9.91M |
| Operating Income | Q1 2025 · Mar 31, 2025 | −$678.53K |
| Operating Income restated | Q1 2025 · Mar 31, 2024 | −$426.6K |
| Cost Of Revenue | Q1 2025 · Mar 31, 2025 | $2.97M |
| Cost Of Revenue restated | Q1 2025 · Mar 31, 2024 | $2.7M |